A novel intracellular 7TM estrogen receptor in breast

描述（由申请人提供）：雌激素是人体中的一种重要激素，调节许多不同的生理作用，包括许多组织的生长、发育和体内平衡。雌激素在正常乳腺组织的发育中起着关键作用，而对雌激素的反应性是乳腺癌患者最重要的预后和治疗因素之一。这些特性中的许多已经归因于雌激素（ER）的可溶性受体，其在很大程度上作为配体激活的转录因子起作用。我们已经表征了一种新的细胞内，7跨膜，G蛋白偶联雌激素受体（GPR 30），我们提出与ER一起调节细胞和组织对雌激素的反应性。我们发现GPR 30主要存在于内质网中。目的1的目标是确定GPR 30内调节其细胞位置的序列。我们还开发了一种新的荧光雌激素衍生物家族，其结合ER和GPR 30。在目标2中，我们将使用这些荧光雌激素开发基于细胞的雌激素结合试验GPR 30，并确定结合特异性和亲和力的雌激素相关化合物的集合。最近，我们的特点是新的GPRSO介导的信号转导通路在乳腺癌细胞。3，4，5-三磷酸磷脂酰肌醇的核积累是由雌激素介导的表皮生长因子受体（EGFR）通过GPR 30的反式激活启动的。目的3的目标是研究EGFR磷酸化和内化相关的EGFR反式激活机制，从而导致转录激活和细胞生长控制。最后，我们建立了GPR 30基因敲除小鼠的群体，以研究GPR 30在乳腺生长发育中的体内功能。在目的4中，我们将表征野生型小鼠中GPR 30的表达并分析GPR 30缺失小鼠的表型。我们还将表征其中GPR 30和经典ER均被删除的小鼠的表型。有了这些工具，我们可以在基因定义的背景下解决GPR 30的雌激素响应信号传导。提出的实验将是非常宝贵的，在定义这种新的雌激素反应性受体在雌激素介导的生长，增殖和分化中的正常发育，以及在肿瘤进展和乳腺癌的治疗的作用。

DESCRIPTION (provided by applicant): Estrogen is a crucial hormone in the human body, regulating many diverse physiological effects, including the growth, development and homeostasis of numerous tissues. Estrogen plays a critical role in the development of normal breast tissue, whereas responsiveness to estrogen represents one of the most important prognostic and therapeutic factors for patients with breast cancer. Many of these properties have been attributed to a soluble receptor for estrogen (ER) that functions in large part as a ligand-activated transcription factor. We have characterized a novel intracellular, 7-transmembrane spanning, G protein- coupled estrogen receptor (GPR30) that we propose functions alongside ER to regulate cell and tissue responsiveness to estrogen. We have discovered that GPR30 resides predominantly in the endoplasmic reticulum. The goal of Aim 1 is to determine the sequences within GPR30 that regulate its cellular location. We have also developed a novel family of fluorescent estrogen derivatives that binds to both the ER and GPR30. In Aim 2 we will use these fluorescent estrogens to develop cell-based estrogen binding assays for GPR30 and determine the binding specificities and affinities of a collection of estrogen-related compounds. Recently, we have characterized novel GPRSO-mediated signal transduction pathways in breast cancer cells. The nuclear accumulation of phosphatidylinositol 3,4,5-trisphosphate is initiated by estrogen-mediated transactivation of epidermal growth factor receptor (EGFR) by GPR30. The goal of Aim 3 is to investigate the mechanisms involved in EGFR transactivation with respect to EGFR phosphorylation and internalization, leading to transcriptional activation and cell growth control. Finally, we have established a colony of GPR30 null mice to dissect the in vivo function of GPR30 in breast growth and development. In Aim 4, we will characterize GPR30 expression in wild type mice and analyze the phenotypes of GPR30 null mice. We will also characterize the phenotypes of mice in which both GPR30 and the classical ERs have been deleted. With these tools, we can address estrogen-responsive signaling of GPR30 in a genetically defined background. The experiments proposed will be invaluable in defining the roles of this novel estrogen- responsive receptor in estrogen-mediated growth, proliferation, and differentiation in normal development as well as in neoplastic progression and the treatment of breast cancer.